title: A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
abstract: OBJECTIVE
  The goal of this study was to assess the efficacy and tolerability of lis-dexamfetamine dimesylate (LDX) as an adjunct to nicotine replacement therapy in adult smokers with ADHD who were undergoing a quit attempt.
  
  
  METHODS
  Thirty-two regular adult smokers with ADHD were randomized to receive LDX (n = 17) or placebo (n = 15) in addition to nicotine patch concurrent with a quit attempt.
  
  
  RESULTS
  There were no differences between smokers assigned to LDX versus placebo in any smoking outcomes. Participants treated with LDX demonstrated significant reductions in self-reported and clinician-rated ADHD symptoms. LDX was well tolerated in smokers attempting to quit.
  
  
  CONCLUSIONS
  In general, LDX does not facilitate smoking cessation in adults with ADHD more than does placebo, though both groups significantly reduced smoking. LDX demonstrated efficacy for reducing ADHD symptoms in adult smokers engaging in a quit attempt.
authors.affiliation: 1Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.
authors.forename: Scott H
authors.initials: SH
authors.lastname: Kollins
authors.forename: Joseph S
authors.initials: JS
authors.lastname: English
authors.forename: Nilda
authors.initials: N
authors.lastname: Itchon-Ramos
authors.forename: Allan K
authors.initials: AK
authors.lastname: Chrisman
authors.forename: Rachel
authors.initials: R
authors.lastname: Dew
authors.forename: Benjamin
authors.initials: B
authors.lastname: O'Brien
authors.forename: F Joseph
authors.initials: FJ
authors.lastname: McClernon
mesh_terms: D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000627:therapeutic use*; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D008297:Male; D010865:Pilot Projects; D012907:Smoking / Q000009:adverse effects*; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine